News CATEGORIES NEWS EVENTS THOUGHT LEADERSHIP & OTHER MEDIA CONTACT THE MEDIA TEAM If you are a journalist with questions or an interview or media request, please do not hesitate to contact us. CONTACT US ARCHIVE November 2021 (1) September 2021 (1) August 2021 (4) July 2021 (1) June 2021 (2) see all RECENT POSTS AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer AGC Biologics Expands pDNA and mRNA Manufacturing Capacity AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer by Press Release on 11/1/21 6:00 AM News SEATTLE – November 1, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams. LEARN MORE AGC Biologics Expands pDNA and mRNA Manufacturing Capacity by Nick McDonald on 9/13/21 5:00 PM News AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects. LEARN MORE AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site by Matteo Pellegrino on 8/20/21 10:30 AM News (COPENHAGEN), August 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients’ needs. LEARN MORE AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site by Matteo Pellegrino on 8/9/21 10:00 PM News (LONGMONT), August 9, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment to oversee strategic development and operational excellence in large-scale C&GT production at its Longmont site in Colorado. Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site Head. LEARN MORE AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings by Matteo Pellegrino on 8/5/21 9:00 AM News AGC Biologics acquires Longmont, Colorado facility to expand its global footprint and increase its C&GT process development and GMP capacity (SEATTLE), August 5, 2021 – AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the finalization of the purchase of a state-of-the-art commercial manufacturing facility in Longmont, Colorado, USA. The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to expand its global end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers. LEARN MORE AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site by Matteo Pellegrino on 8/2/21 11:00 AM News (SEATTLE), August 2, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the strategic development and operational excellence in clinical and commercial biologics production at its Seattle, Washington site. Effective August 2, 2021, Kevin Ingham will join the Seattle team as the General Manager/Site Head. LEARN MORE AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings by Matteo Pellegrino on 7/1/21 9:00 AM News (SEATTLE), July 1, 2021 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will equip AGC Biologics with significant additional capacity and space to continue to expand its end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers. This facility is only 16 miles from AGC Biologics’ state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO. LEARN MORE Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III by Matteo Pellegrino on 6/23/21 5:30 AM News TEL AVIV, Israel and SEATTLE, Wash. June 21, 2021 – Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness. LEARN MORE AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine by David Self on 6/7/21 7:00 AM News AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility. LEARN MORE AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics by David Self on 5/19/21 10:06 AM News (SEATTLE), May 19, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others. This award is dedicated to showcasing the best of the Italian M&A market. LEARN MORE ALL POSTS NEXT PAGE Follow Us ABOUT CAPABILITIES RESOURCES FACILITIES NEWS & EVENTS LEGAL & COMPLIANCE CONTACT US Follow us on LinkedIn Follow us on Twitter Follow us on Facebook NEWS AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer AGC Biologics Expands pDNA and mRNA Manufacturing Capacity AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings EVENTS Cell & Gene Meeting on the Mesa, October 12-14, 2021 AGC Biologics is Attending BIO Asia-Taiwan July 23-26, 2021 Presenting Our Biological and Cell & Gene Therapy Capabilities AGC Biologics is Attending ASGCT May 11-14, 2021 and Presenting Our Scalable LVV Production Process and Large-Scale AAV Manufacturing Development Data AGC Biologics is Attending Meeting on the Med, April 6-9, 2021 FACILITIES SEATTLE, WASHINGTON (Headquarters) BOULDER, COLORADO LONGMONT, COLORADO COPENHAGEN, DENMARK HEIDELBERG, GERMANY MILAN, ITALY CHIBA, JAPAN ©2021 AGC Biologics. All Rights Reserved. Website Privacy Policy